Kintara Therapeutics, Inc. (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive the group's Phase 2/3 clinical trial to treat glioblastoma multiforme has been activated in 15 US sites as of May 14, 2021.
Zarrabian says the design trial and execution is 'critical' and he's pleased with the progress the trial has made thus far. GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM.